Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...
Check Point® Software Technologies Ltd. (NASDAQ:CHKP), a leading cyber security platform provider, signs a definitive agreement...
HC Wainwright & Co. analyst Joseph Pantginis maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and lowers the p...
Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate ...
Cosibelimab is its anti-programmed death ligand-1 ("PD-L1") antibody, as a potential new treatment for adults with meta...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...
Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the a...
Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology compan...
